原发性黏液性卵巢癌组织学亚型对生存结局的临床意义
研究分析2003至2021年131例原发性黏液性卵巢癌患者,按2014年WHO分类分为膨胀型(ES)和浸润型(IS)。中位随访55.9个月,27例(20.6%)复发、20例(15.3%)死亡;IS与晚期、淋巴结受累、术后残留更常见及更差预后相关,但多因素分析中IS无统计学显著性。
要点
- 浸润型亚型与晚期、淋巴结受累和术后残留病变更常见,预后更差。
- 多因素分析中晚期和术后残留与更差生存相关,浸润型亚型无统计学显著性。
- I期患者中浸润型接受保留生育手术者5年无进展生存率83.3%,低于未保留生育者。
核心结论
- 原发性黏液性卵巢癌浸润型亚型生存结局更差且晚期肿瘤比例更高,其独立预后意义尚不确定。
- 作者认为浸润型亚型中接受保留生育手术的患者应考虑辅助化疗。
研究设计与样本
- 回顾性分析2003至2021年间接受初次手术的131例原发性黏液性卵巢癌患者资料,收集体线特征、手术和病理信息,计算生存结局并分析影响因素。
主要发现
- 中位随访55.9个月,27例(20.6%)复发,20例(15.3%)死亡。
- 131例中113例经切片复核分类为87例(77%)膨胀型和26例(23%)浸润型。
- 浸润型中晚期、淋巴结受累和术后残留肿瘤更常见,预后更差。
- 多因素分析中晚期和术后残留与更差生存相关,浸润型无统计学显著性。
- I期亚组分析中不同亚型间生存无差异;浸润型接受保留生育手术者5年无进展生存率83.3%,低于未保留生育者(膨胀型5年无进展生存率97.9%,P=0.002;浸润型5年无进展生存率100%,P=0.001)。
临床怎么用
- 作者建议浸润型亚型中接受保留生育手术的患者应考虑辅助化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In 2014, the World Health Organization introduced a new histologic classification by dividing primary mucinous ovarian carcinoma (PMOC) into two: expansile (ES) or infiltrative subtypes (IS). This study investigated the clinical implications of these histological subtypes on survival outcomes. METHODS: Data from 131 patients with PMOC who underwent primary surgery between 2003 and 2021 were analyzed. The patients baseline characteristics, surgical and pathological information were collected. Survival outcomes were calculated, while factors affecting them were also investigated. RESULTS: During 55.9 months of median follow-up, 27 (20.6%) patients experienced recurrence and 20 (15.3%) died. Among 131 patients, 113 patients were classified into 87 (77%) ES and 26 (23%) IS after a slide review. Advanced stage, lymph node involvement, and residual tumors after surgery were more common in the IS, showing poorer prognosis. In multivariate analyses, advanced stage and residual tumors after surgery were associated with worse survival, while the IS showed no statistical significance. In subgroup analysis for stage I disease, survival did not vary between subtypes. Nevertheless, patients in the IS group who underwent fertility-sparing surgeries demonstrated a 5-year progression-free survival (PFS) rate of 83.3%, significantly lower than patients without fertility preservation, irrespective of histologic subtypes (5-year PFS rate: 97.9%; P = 0.002 for the ES, 5-year PFS rate: 100%; P = 0.001 for the IS). CONCLUSIONS: The IS of PMOC had poorer survival outcomes and a higher proportion of advanced-stage tumors. Although its independent prognostic significance remains uncertain, adjuvant chemotherapy should be considered for patients with fertility preservation in the IS group.
引用
- Lim H, Ju Y, Kim SI, et al. Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma. Gynecol Oncol. 2023. PMID: 37660413. doi:10.1016/j.ygyno.2023.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。